Reefer Sanity
Receipts

Every source, in one place.

148 citations: peer-reviewed studies, federal agencies, laws, and reputable reporting. Click any number on the site to jump here.

Links checked November 14, 2026. A few government and news sites block automated checkers, but they open normally in a browser.

  1. 1
    Peer-reviewed study
    Lachenmeier DW, Rehm J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Scientific Reports. 2015;5:8126. doi:10.1038/srep08126
    https://www.nature.com/articles/srep08126
  2. 2
    Peer-reviewed study
    Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010;376(9752):1558–1565. PMID 21036393
    https://pubmed.ncbi.nlm.nih.gov/21036393/
  3. 3
    Government data
    Centers for Disease Control and Prevention. Facts About U.S. Deaths from Excessive Alcohol Use.
    https://www.cdc.gov/alcohol/facts-stats/index.html
  4. 4
    Government report
    Esser MB, Sherk A, Liu Y, Naimi TS. Deaths from Excessive Alcohol Use — United States, 2016–2021. MMWR. 2024;73(8):154–161.
    https://www.cdc.gov/mmwr/volumes/73/wr/mm7308a1.htm
  5. 5
    International agency
    World Health Organization. Alcohol — fact sheet (data from the 2024 Global status report on alcohol and health).
    https://www.who.int/news-room/fact-sheets/detail/alcohol
  6. 6
    Peer-reviewed study
    GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016. The Lancet. 2018;392:1015–1035. PMID 30146330
    https://pubmed.ncbi.nlm.nih.gov/30146330/
  7. 7
    Government report
    U.S. Surgeon General. Alcohol and Cancer Risk (Advisory), January 2025.
    https://www.hhs.gov/surgeongeneral/reports-and-publications/alcohol-cancer/index.html
  8. 8
    Peer-reviewed study
    Lopez-Quintero C, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the NESARC. Drug and Alcohol Dependence. 2011;115(1-2):120–130. PMID 21145178
    https://pubmed.ncbi.nlm.nih.gov/21145178/
  9. 9
    Systematic review & meta-analysis
    Leung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? Addictive Behaviors. 2020;109:106479. PMID 32485547
    https://pubmed.ncbi.nlm.nih.gov/32485547/
  10. 10
    National Academies report
    National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017.
    https://www.nationalacademies.org/publications/24625
  11. 11
    National Academies report
    NASEM (2017). Report in brief: Committee's conclusions (one-page list of all ~100 conclusions with evidence grades).
    https://nap.nationalacademies.org/resource/24625/Cannabis_committee_conclusions.pdf
  12. 12
    Government guidance
    Centers for Disease Control and Prevention. Cannabis Health Effects.
    https://www.cdc.gov/cannabis/health-effects/index.html
  13. 13
    Peer-reviewed study
    Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduction Journal. 2009;6:35. PMID 19958538
    https://pubmed.ncbi.nlm.nih.gov/19958538/
  14. 14
    Peer-reviewed study
    Lucas P, et al. Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada. International Journal of Drug Policy. 2020;86:102963. PMID 33068830
    https://pubmed.ncbi.nlm.nih.gov/33068830/
  15. 15
    Peer-reviewed study
    Karoly HC, et al. Effects of cannabis use on alcohol consumption in a sample of treatment-engaged heavy drinkers in Colorado. Addiction. 2021;116(9):2529–2537. PMID 33464670
    https://pubmed.ncbi.nlm.nih.gov/33464670/
  16. 16
    Peer-reviewed review
    Subbaraman MS. Can cannabis be considered a substitute medication for alcohol? Alcohol and Alcoholism. 2014;49(3):292–298. PMID 24402247
    https://pubmed.ncbi.nlm.nih.gov/24402247/
  17. 17
    Peer-reviewed study
    Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. PNAS. 2019;116(26):12624–12626. PMID 31182592
    https://pubmed.ncbi.nlm.nih.gov/31182592/
  18. 18
    Peer-reviewed study
    Wang M, et al. Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using UHPSFC/PDA-MS. Cannabis and Cannabinoid Research. 2016;1(1):262–271. PMID 28861498
    https://pubmed.ncbi.nlm.nih.gov/28861498/
  19. 19
    Peer-reviewed review
    Moreno-Sanz G. Can You Pass the Acid Test? Critical Review and Novel Therapeutic Perspectives of Δ9-Tetrahydrocannabinolic Acid A. Cannabis and Cannabinoid Research. 2016;1(1):124–130. PMID 28861488
    https://pubmed.ncbi.nlm.nih.gov/28861488/
  20. 20
    Systematic review & meta-analysis
    Whiting PF, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. PMID 26103030
    https://pubmed.ncbi.nlm.nih.gov/26103030/
  21. 21
    Government guidance
    U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process.
    https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process
  22. 22
    Randomized controlled trial
    Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376:2011–2020. PMID 28538134
    https://pubmed.ncbi.nlm.nih.gov/28538134/
  23. 23
    Peer-reviewed study
    Meier MH, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. PNAS. 2012;109(40):E2657–E2664. PMID 22927402
    https://pubmed.ncbi.nlm.nih.gov/22927402/
  24. 24
    Systematic review
    Sorensen CJ, et al. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment — a Systematic Review. Journal of Medical Toxicology. 2017;13(1):71–87. PMID 28000146
    https://pubmed.ncbi.nlm.nih.gov/28000146/
  25. 25
    Peer-reviewed review
    Hartman RL, Huestis MA. Cannabis effects on driving skills. Clinical Chemistry. 2013;59(3):478–492. PMID 23220273
    https://pubmed.ncbi.nlm.nih.gov/23220273/
  26. 26
    Government guidance
    Centers for Disease Control and Prevention. Cannabis and Poisoning.
    https://www.cdc.gov/cannabis/health-effects/poisoning.html
  27. 27
    Government guidance
    Health Canada. What you need to know if you choose to consume cannabis. 2019.
    https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/resources/what-you-need-to-know-if-you-choose-to-consume-cannabis.html
  28. 28
    Government guidance
    Centers for Disease Control and Prevention. Cannabis and Pregnancy.
    https://www.cdc.gov/cannabis/health-effects/pregnancy.html
  29. 29
    Federal law
    7 U.S.C. § 1639o — Definitions (hemp), including the 2025 amendment and its effective-date notes.
    https://uscode.house.gov/us/usc/119-142/t7/s1639o/
  30. 30
    Congressional Research Service
    Congressional Research Service. Change to Federal Definition of Hemp and Implications for Federal Enforcement (IN12620).
    https://www.congress.gov/crs-product/IN12620
  31. 31
    Legal analysis
    Womble Bond Dickinson (via JD Supra). Hemp Restrictions Start November 12, 2026, but Key Questions Remain. Nov 13, 2026.
    https://www.jdsupra.com/legalnews/hemp-restrictions-start-november-12-1243411/
  32. 32
    State government guidance
    Iowa HHS. Consumable Hemp — Federal Hemp Law Changes & FAQs (summarizes the Nov 12 and Dec 11, 2026 federal dates).
    https://hhs.iowa.gov/health-prevention/consumable-hemp/consumable-hemp-federal-hemp-law-changes-faqs
  33. 33
    Federal Register
    DOJ final rule: Rescheduling of FDA-Approved Products Containing Marijuana (and marijuana under a state medical license) From Schedule I to Schedule III. 91 FR, April 28, 2026.
    https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products
  34. 34
    Government press release
    U.S. Department of Justice. Justice Department Announces Issuance of Federal Registrations for Medical Marijuana Dispensaries.
    https://www.justice.gov/opa/pr/justice-department-announces-issuance-federal-registrations-medical-marijuana-dispensaries
  35. 35
    Government page
    U.S. Drug Enforcement Administration. Marijuana Rescheduling Regulatory Actions.
    https://www.dea.gov/marijuana-rescheduling-regulatory-actions
  36. 36
    State government guidance
    Tennessee Alcoholic Beverage Commission. Frequently Asked Questions — hemp-derived cannabinoid regulation (Public Chapter 526, 2025).
    https://www.tn.gov/abc/public-information-and-forms/frequently-asked-questions.html
  37. 37
    State legislation
    Tennessee General Assembly. HB1376 / SB1413 (114th GA) — bill history and amendments (became Public Chapter 526).
    https://wapp.capitol.tn.gov/apps/BillInfo/Default?BillNumber=HB1376&ga=114
  38. 38
    News report
    WKRN/WATE. TN law banning THCA products takes full effect July 1 (2026).
    https://www.wate.com/news/tennessee/tennessees-thca-ban-to-take-full-effect-july-1/
  39. 39
    News report
    NewsChannel 5 Nashville. New Tennessee hemp laws take effect July 1 (2026).
    https://www.newschannel5.com/news/state/tennessee/davidson-county/new-tennessee-hemp-laws-take-effect-july-1-causing-some-businesses-to-close-relocate-or-adapt
  40. 40
    State law
    Tenn. Code Ann. § 39-17-418 — Simple possession or casual exchange.
    https://law.justia.com/codes/tennessee/title-39/chapter-17/part-4/section-39-17-418/
  41. 41
    Legal reference
    FindLaw. Tennessee Marijuana Laws.
    https://www.findlaw.com/state/tennessee-law/tennessee-marijuana-laws.html
  42. 42
    Government health reference
    MedlinePlus (U.S. National Library of Medicine). Alcohol withdrawal.
    https://medlineplus.gov/ency/article/000764.htm
  43. 43
    Randomized placebo-controlled trial
    Naftali T, et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013;11(10):1276–1280. PMID 23648372
    https://pubmed.ncbi.nlm.nih.gov/23648372/
  44. 44
    Prospective study
    Bonn-Miller MO, et al. The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder. Cannabis and Cannabinoid Research. 2022;7(2):214–223. PMID 33998874
    https://pubmed.ncbi.nlm.nih.gov/33998874/
  45. 45
    Systematic review
    Orsolini L, et al. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina. 2019;55(9):525. PMID 31450833
    https://pubmed.ncbi.nlm.nih.gov/31450833/
  46. 46
    Peer-reviewed study (preclinical)
    Nadal X, et al. Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. British Journal of Pharmacology. 2017;174(23):4263–4276. PMID 28853159
    https://pubmed.ncbi.nlm.nih.gov/28853159/
  47. 47
    Peer-reviewed study (preclinical)
    Rock EM, et al. Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. British Journal of Pharmacology. 2013;170(3):641–648. PMID 23889598
    https://pubmed.ncbi.nlm.nih.gov/23889598/
  48. 48
    Peer-reviewed study (preclinical, NIH)
    Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. PNAS. 1998;95(14):8268–8273. PMID 9653176
    https://pubmed.ncbi.nlm.nih.gov/9653176/
  49. 49
    U.S. patent
    U.S. Patent No. 6,630,507 B1, “Cannabinoids as antioxidants and neuroprotectants.” Assignee: United States of America as represented by the Department of Health and Human Services. Granted Oct 7, 2003.
    https://patents.google.com/patent/US6630507
  50. 50
    Peer-reviewed study
    Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population. JAMA Internal Medicine. 2018;178(5):667–672. PMID 29610897
    https://pubmed.ncbi.nlm.nih.gov/29610897/
  51. 51
    Peer-reviewed study
    Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. International Journal of Drug Policy. 2017;42:30–35. PMID 28189912
    https://pubmed.ncbi.nlm.nih.gov/28189912/
  52. 52
    Peer-reviewed study
    Lucas P, et al. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances. Harm Reduction Journal. 2019;16:9. PMID 30691503
    https://pubmed.ncbi.nlm.nih.gov/30691503/
  53. 53
    Peer-reviewed study
    Anderson DM, Rees DI, Sabia JJ, Safford S. Association of Marijuana Legalization With Marijuana Use Among US High School Students, 1993–2019. JAMA Network Open. 2021;4(9):e2124638. PMID 34491352
    https://pubmed.ncbi.nlm.nih.gov/34491352/
  54. 54
    Federal Register
    DOJ/DEA. Schedules of Controlled Substances: Rescheduling of Marijuana (proposed rule). 89 FR 44597, May 21, 2024.
    https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
  55. 55
    Government report
    HHS / FDA. Basis for the Recommendation to Reschedule Marijuana into Schedule III of the Controlled Substances Act (Aug 2023).
    https://www.hhs.gov/sites/default/files/scheduling-recommendation.pdf
  56. 56
    Civil-rights report
    ACLU. A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform (2020) — press release.
    https://www.aclu.org/press-releases/new-aclu-report-despite-marijuana-legalization-black-people-still-almost-four-times
  57. 57
    Advocacy-group tally of state data
    Marijuana Policy Project. Cannabis Tax Revenue in States that Regulate Cannabis for Adult Use (compiled from state revenue reports).
    https://www.mpp.org/assets/pdf/issues/legalization/cannabis-tax-revenue-states-regulate-cannabis-adult-use.pdf
  58. 58
    Journalism (PBS)
    PBS FRONTLINE. Marijuana Timeline — “Busted: America's War on Marijuana.”
    https://www.pbs.org/wgbh/pages/frontline/shows/dope/etc/cron.html
  59. 59
    Journalism
    Adams C. The man behind the marijuana ban for all the wrong reasons. CBS News, Nov 17, 2016.
    https://www.cbsnews.com/news/harry-anslinger-the-man-behind-the-marijuana-ban/
  60. 60
    Primary source
    Anslinger HJ, Cooper CR. “Marijuana — Assassin of Youth.” The American Magazine, July 1937 (condensed in Reader's Digest, Feb 1938; transcription at the Schaffer Library). Archived copy at the Internet Archive; alternate transcription: druglibrary.net
    https://web.archive.org/web/20210211181216/http://druglibrary.org/mags/assassinofyouth.htm
  61. 61
    Scholarly history
    Bonnie RJ, Whitebread CH. The Marihuana Conviction: A History of Marihuana Prohibition in the United States — chapter “Nonchalance on Capitol Hill” (1937 hearings and Dr. William Woodward's AMA testimony).
    https://www.drugtext.org/library/cannabis/the-marihuana-conviction/nonchalance-on-capitol-hill
  62. 62
    Journalism
    Sullum J. 50 Years After Nixon's Commission Said Cops Should Stop Busting Pot Users... Reason, Mar 22, 2022 (quotes the 1972 Shafer Commission report).
    https://reason.com/2022/03/22/50-years-after-nixons-commission-said-cops-should-stop-busting-pot-users-the-federal-ban-remains-unchanged/
  63. 63
    Journalism
    Baum D. Legalize It All. Harper's Magazine, April 2016.
    https://harpers.org/archive/2016/04/legalize-it-all/
  64. 64
    Journalism
    CNN. Report: Nixon aide says war on drugs targeted blacks, hippies. Mar 23, 2016 (includes the Ehrlichman family's response).
    https://www.cnn.com/2016/03/23/politics/john-ehrlichman-richard-nixon-drug-war-blacks-hippie
  65. 65
    Journalism
    Ingraham C. A maker of deadly painkillers is bankrolling the opposition to legal marijuana in Arizona. Washington Post, Sep 9, 2016.
    https://www.washingtonpost.com/news/wonk/wp/2016/09/09/a-maker-of-deadly-painkillers-is-bankrolling-the-opposition-to-legal-marijuana-in-arizona/
  66. 66
    Journalism
    Phoenix New Times. Arizona Drug Firm Insys Makes Synthetic Pot Compound, Spends Big to Defeat Legal Pot. 2016.
    https://www.phoenixnewtimes.com/news/arizona-drug-firm-insys-makes-synthetic-pot-compound-spends-big-to-defeat-legal-pot-8628614/
  67. 67
    Government press release
    U.S. Attorney's Office, District of Massachusetts. Founder and Four Executives of Insys Therapeutics Convicted of Racketeering Conspiracy. May 2, 2019.
    https://www.justice.gov/usao-ma/pr/founder-and-four-executives-insys-therapeutics-convicted-racketeering-conspiracy
  68. 68
    Journalism (campaign-finance records)
    WBUR. A Look At The Money For And Against Legalized Marijuana In Mass. Oct 20, 2016.
    https://www.wbur.org/morningedition/2016/10/20/marijuana-ballot-question-money
  69. 69
    Journalism
    New York Magazine. Big Beer Takes on Little Weed at the Ballot Box. Sep 2016.
    https://nymag.com/intelligencer/2016/09/big-beer-takes-on-little-weed-at-the-ballot-box.html
  70. 70
    Journalism (campaign-finance records)
    Fang L. Police and Prison Guard Groups Fight Marijuana Legalization in California. The Intercept, May 18, 2016.
    https://theintercept.com/2016/05/18/ca-marijuana-measure/
  71. 71
    Journalism (lobbying disclosures)
    Fang L. The Top Five Special Interest Groups Lobbying To Keep Marijuana Illegal. Republic Report, 2012.
    https://www.republicreport.org/2012/marijuana-lobby-illegal/
  72. 72
    Government guidance
    National Institute on Drug Abuse. Cannabis (Marijuana) — research topic page (“Is cannabis a gateway drug?”).
    https://nida.nih.gov/research-topics/cannabis-marijuana
  73. 73
    Peer-reviewed study
    Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Internal Medicine. 2014;174(10):1668–1673. PMID 25154332
    https://pubmed.ncbi.nlm.nih.gov/25154332/
  74. 74
    Peer-reviewed study
    Wen H, Hockenberry JM. Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees. JAMA Internal Medicine. 2018;178(5):673–679. PMID 29610827
    https://pubmed.ncbi.nlm.nih.gov/29610827/
  75. 75
    Peer-reviewed study
    Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. Journal of Pain. 2016;17(6):739–744. PMID 27001005
    https://pubmed.ncbi.nlm.nih.gov/27001005/
  76. 76
    Peer-reviewed study
    Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLoS One. 2017;12(11):e0187795. PMID 29145417
    https://pubmed.ncbi.nlm.nih.gov/29145417/
  77. 77
    Peer-reviewed study
    Livingston MD, Barnett TE, Delcher C, Wagenaar AC. Recreational Cannabis Legalization and Opioid-Related Deaths in Colorado, 2000-2015. American Journal of Public Health. 2017;107(11):1827–1829. PMID 29019782
    https://pubmed.ncbi.nlm.nih.gov/29019782/
  78. 78
    Peer-reviewed study
    Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? Journal of Health Economics. 2018;58:29–42. PMID 29408153
    https://pubmed.ncbi.nlm.nih.gov/29408153/
  79. 79
    Peer-reviewed study
    Corroon JM Jr, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs – a cross-sectional study. Journal of Pain Research. 2017;10:989–998. PMID 28496355
    https://pubmed.ncbi.nlm.nih.gov/28496355/
  80. 80
    Peer-reviewed study
    Hsu G, Kovács B. Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study. BMJ. 2021;372:m4957. PMID 33504472
    https://pubmed.ncbi.nlm.nih.gov/33504472/
  81. 81
    Peer-reviewed study
    Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug and Alcohol Dependence. 2017;173:144–150. PMID 28259087
    https://pubmed.ncbi.nlm.nih.gov/28259087/
  82. 82
    Peer-reviewed study
    Lopez CD, et al. State Medical Cannabis Laws Associated With Reduction in Opioid Prescriptions by Orthopaedic Surgeons in Medicare Part D Cohort. Journal of the American Academy of Orthopaedic Surgeons. 2021;29(4):e188–e197. PMID 32404683
    https://pubmed.ncbi.nlm.nih.gov/32404683/
  83. 83
    Systematic review
    Risso C, Boniface S, Subbaraman MS, Englund A. Does cannabis complement or substitute alcohol consumption? A systematic review of human and animal studies. Journal of Psychopharmacology. 2020;34(9):938–954. PMID 32648806
    https://pubmed.ncbi.nlm.nih.gov/32648806/
  84. 84
    Systematic review
    De Aquino JP, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug and Alcohol Dependence. 2022;241:109702. PMID 36434879
    https://pubmed.ncbi.nlm.nih.gov/36434879/
  85. 85
    Systematic review & meta-analysis
    Costa GPA, et al. The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies. American Journal of Drug and Alcohol Abuse. 2024;50(1):12–26. PMID 38225727
    https://pubmed.ncbi.nlm.nih.gov/38225727/
  86. 86
    Randomized controlled trial
    Metrik J, Aston ER, Gunn RL, Swift R, MacKillop J, Kahler CW. Acute Effects of Cannabis on Alcohol Craving and Consumption: A Randomized Controlled Crossover Trial. American Journal of Psychiatry. 2026;183(2):134–143 (published online Nov 2025). PMID 41254853
    https://pubmed.ncbi.nlm.nih.gov/41254853/
  87. 87
    Peer-reviewed study
    Baggio M, Chong A, Kwon S. Marijuana and alcohol: Evidence using border analysis and retail sales data. Canadian Journal of Economics. 2020;53(2):563–591. doi:10.1111/caje.12437
    https://doi.org/10.1111/caje.12437
  88. 88
    Government data
    Centers for Disease Control and Prevention. Understanding the Opioid Overdose Epidemic.
    https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html
  89. 89
    Government data
    National Institute on Alcohol Abuse and Alcoholism. Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics (2024 NSDUH data).
    https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics
  90. 90
    Randomized controlled trial
    Thiele EA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2018;391(10125):1085–1096. PMID 29395273
    https://pubmed.ncbi.nlm.nih.gov/29395273/
  91. 91
    Randomized controlled trial
    Devinsky O, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. New England Journal of Medicine. 2018;378:1888–1897. PMID 29768152
    https://pubmed.ncbi.nlm.nih.gov/29768152/
  92. 92
    Randomized controlled trial
    Thiele EA, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurology. 2021;78(3):285–292. PMID 33346789
    https://pubmed.ncbi.nlm.nih.gov/33346789/
  93. 93
    Randomized controlled trial
    Grimison P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology. 2020;31(11):1553–1560. PMID 32801017
    https://pubmed.ncbi.nlm.nih.gov/32801017/
  94. 94
    Randomized controlled trial
    Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex) as add-on therapy in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology. 2011;18(9):1122–1131. PMID 21362108
    https://pubmed.ncbi.nlm.nih.gov/21362108/
  95. 95
    Randomized controlled trial
    Abrams DI, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–521. PMID 17296917
    https://pubmed.ncbi.nlm.nih.gov/17296917/
  96. 96
    Randomized controlled trial
    Wilsey B, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain. 2013;14(2):136–148. PMID 23237736
    https://pubmed.ncbi.nlm.nih.gov/23237736/
  97. 97
    Randomized controlled trial
    Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226. PMID 21307846
    https://pubmed.ncbi.nlm.nih.gov/21307846/
  98. 98
    Randomized controlled trial
    Walsh JH, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep. 2021;44(11):zsab149. PMID 34115851
    https://pubmed.ncbi.nlm.nih.gov/34115851/
  99. 99
    Peer-reviewed study
    Rhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. Pharmacotherapy. 2016;36(5):505–510. PMID 26749285
    https://pubmed.ncbi.nlm.nih.gov/26749285/
  100. 100
    Peer-reviewed study
    Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and Long-Term Effects of Cannabis on Headache and Migraine. Journal of Pain. 2020;21(5-6):722–730. PMID 31715263
    https://pubmed.ncbi.nlm.nih.gov/31715263/
  101. 101
    Randomized controlled trial
    Naftali T, et al. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial. Journal of Crohn's and Colitis. 2021;15(11):1799–1806. PMID 33858011
    https://pubmed.ncbi.nlm.nih.gov/33858011/
  102. 102
    Peer-reviewed study
    Habib G, Artul S. Medical Cannabis for the Treatment of Fibromyalgia. Journal of Clinical Rheumatology. 2018;24(5):255–258. PMID 29461346
    https://pubmed.ncbi.nlm.nih.gov/29461346/
  103. 103
    Peer-reviewed study
    Sinclair J, et al. Cannabis Use, a Self-Management Strategy Among Australian Women With Endometriosis: Results From a National Online Survey. Journal of Obstetrics and Gynaecology Canada. 2020;42(3):256–261. PMID 31722852
    https://pubmed.ncbi.nlm.nih.gov/31722852/
  104. 104
    Peer-reviewed study
    Bar-Lev Schleider L, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European Journal of Internal Medicine. 2018;49:37–43. PMID 29482741
    https://pubmed.ncbi.nlm.nih.gov/29482741/
  105. 105
    Executive order
    The White House. Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research. December 18, 2025.
    https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/
  106. 106
    Peer-reviewed review
    Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry. 2016;79(7):516–525. PMID 26698193
    https://pubmed.ncbi.nlm.nih.gov/26698193/
  107. 107
    Peer-reviewed study
    Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society. 1964;86:1646–1647. doi:10.1021/ja01062a046
    https://doi.org/10.1021/ja01062a046
  108. 108
    International agency
    World Health Organization Expert Committee on Drug Dependence. Cannabidiol (CBD): Critical Review Report. 40th meeting, Geneva, June 2018.
    https://cdn.who.int/media/docs/default-source/controlled-substances/whocbdreportmay2018-2.pdf
  109. 109
    Peer-reviewed review
    Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344–1364. PMID 21749363
    https://pubmed.ncbi.nlm.nih.gov/21749363/
  110. 110
    Peer-reviewed study
    Gertsch J, et al. Beta-caryophyllene is a dietary cannabinoid. PNAS. 2008;105(26):9099–9104. PMID 18574142
    https://pubmed.ncbi.nlm.nih.gov/18574142/
  111. 111
    Randomized controlled trial
    Spindle TR, et al. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis. Drug and Alcohol Dependence. 2024;257:111267. PMID 38498958
    https://pubmed.ncbi.nlm.nih.gov/38498958/
  112. 112
    Peer-reviewed review
    Nachnani R, Raup-Konsavage WM, Vrana KE. The Pharmacological Case for Cannabigerol. Journal of Pharmacology and Experimental Therapeutics. 2021;376(2):204–212. PMID 33168643
    https://pubmed.ncbi.nlm.nih.gov/33168643/
  113. 113
    Randomized controlled trial
    Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Scientific Reports. 2024;14:16163. PMID 39003387
    https://pubmed.ncbi.nlm.nih.gov/39003387/
  114. 114
    Peer-reviewed review
    Corroon J. Cannabinol and Sleep: Separating Fact from Fiction. Cannabis and Cannabinoid Research. 2021;6(5):366–371. PMID 34468204
    https://pubmed.ncbi.nlm.nih.gov/34468204/
  115. 115
    Randomized controlled trial
    Bonn-Miller MO, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Experimental and Clinical Psychopharmacology. 2024;32(3):277–284. PMID 37796540
    https://pubmed.ncbi.nlm.nih.gov/37796540/
  116. 116
    Randomized controlled trial
    Jadoon KA, et al. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes. Diabetes Care. 2016;39(10):1777–1786. PMID 27573936
    https://pubmed.ncbi.nlm.nih.gov/27573936/
  117. 117
    Randomized controlled trial
    Englund A, et al. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers. Journal of Psychopharmacology. 2016;30(2):140–151. PMID 26577065
    https://pubmed.ncbi.nlm.nih.gov/26577065/
  118. 118
    Historical archive
    George Washington's Mount Vernon. George Washington Grew Hemp.
    https://www.mountvernon.org/george-washington/farming/washingtons-crops/george-washington-grew-hemp
  119. 119
    Primary-source compilation
    Common Sense for Drug Policy. Nixon Tapes Show Roots of Marijuana Prohibition: Misinformation, Culture Wars and Prejudice (excerpts of declassified 1971–72 Oval Office tapes). March 2002.
    https://www.csdp.org/research/shafernixon.pdf
  120. 120
    Federal law
    21 U.S.C. § 812 — Schedules of controlled substances (Schedule I criteria and list).
    https://www.law.cornell.edu/uscode/text/21/812
  121. 121
    Government memo
    Cole JM, Deputy Attorney General. Memorandum for All United States Attorneys: Guidance Regarding Marijuana Enforcement. U.S. Department of Justice, August 29, 2013.
    https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
  122. 122
    Government memo
    Sessions JB, Attorney General. Memorandum for All United States Attorneys: Marijuana Enforcement. U.S. Department of Justice, January 4, 2018.
    https://www.justice.gov/archives/opa/press-release/file/1022196/dl?inline=
  123. 123
    Presidential statement
    Statement from President Biden on Marijuana Reform. The White House, October 6, 2022.
    https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2022/10/06/statement-from-president-biden-on-marijuana-reform/
  124. 124
    Government press release
    U.S. Department of Justice. Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III. April 2026.
    https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana
  125. 125
    Research center
    Pew Research Center. Most Americans now live in a legal marijuana state – and most have at least one dispensary in their county. Feb 29, 2024.
    https://www.pewresearch.org/short-reads/2024/02/29/most-americans-now-live-in-a-legal-marijuana-state-and-most-have-at-least-one-dispensary-in-their-county/
  126. 126
    Research center (survey)
    Pew Research Center. Most Americans favor legalizing marijuana for medical, recreational use. Mar 26, 2024.
    https://www.pewresearch.org/politics/2024/03/26/most-americans-favor-legalizing-marijuana-for-medical-recreational-use/
  127. 127
    Research center (FBI data)
    Gramlich J. Four-in-ten U.S. drug arrests in 2018 were for marijuana offenses – mostly possession. Pew Research Center, Jan 22, 2020.
    https://www.pewresearch.org/short-reads/2020/01/22/four-in-ten-u-s-drug-arrests-in-2018-were-for-marijuana-offenses-mostly-possession/
  128. 128
    Industry report
    Vangst. 2025 Cannabis Jobs Report (press release via PR Newswire, May 13, 2025).
    https://www.prnewswire.com/news-releases/cannabis-industry-revenue-grows-whilst-jobs-slightly-stall-vangst-jobs-report-finds-302453501.html
  129. 129
    Randomized controlled trial
    Lavender IG, et al. Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial. Journal of Sleep Research. 2026;35(4):e70284. PMID 41698831
    https://pubmed.ncbi.nlm.nih.gov/41698831/
  130. 130
    Federal law
    Public Law 119-103, Continuing Appropriations and Extensions Act, 2027, Sec. 2019 ("Section 781 Extension"). Approved Sept. 2, 2026. GovInfo.
    https://www.govinfo.gov/content/pkg/PLAW-119publ103/html/PLAW-119publ103.htm
  131. 131
    Congress.gov
    H.R. 6500, Continuing Appropriations and Extensions Act, 2027. Bill status: signed by the President and became Public Law 119-103 on Sept. 2, 2026.
    https://www.congress.gov/bill/119th-congress/house-bill/6500/all-actions
  132. 132
    White House
    The White House. Congressional Bill H.R. 6500 Signed into Law. Sept. 2, 2026.
    https://www.whitehouse.gov/briefings-statements/2026/09/congressional-bill-h-r-6500-signed-into-law/
  133. 133
    Congressional Research Service
    Congressional Research Service. Delay in Changes to Hemp Definition: Cannabinoids Not Capable of Being Naturally Produced by the Cannabis Plant (LSB11496).
    https://www.everycrsreport.com/reports/LSB11496.html
  134. 134
    News
    Marijuana Moment. Trump Signs Bill To Delay Hemp THC Product Ban, Giving Lawmakers More Time To Craft Regulations Instead Of Prohibition. Sept. 3, 2026.
    https://www.marijuanamoment.net/trump-signs-bill-to-delay-hemp-thc-product-ban-giving-lawmakers-more-time-to-craft-regulations-instead-of-prohibition/
  135. 135
    News
    NPR (Frank Morris, KCUR). Some states get a head start on upcoming federal hemp ban. Nov. 12, 2026.
    https://www.npr.org/2026/11/12/nx-s1-6035839/some-states-get-a-head-start-on-upcoming-federal-hemp-ban
  136. 136
    Peer-reviewed study
    ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency Over the Last 2 Decades (1995–2014): Analysis of Current Data in the United States. Biological Psychiatry. 2016;79(7):613–619. PMID 26903403
    https://pubmed.ncbi.nlm.nih.gov/26903403/
  137. 137
    Journalism (campaign-finance records)
    Hamilton K. Here's who bankrolls the fight against marijuana legalization. VICE News, Oct 26, 2016.
    https://www.vice.com/en/article/heres-who-bankrolls-the-fight-against-marijuana-legalization/
  138. 138
    Journalism (campaign-finance records)
    Fang L. GOP Mogul Behind Drug Rehab 'Torture' Centers Is Bankrolling Opposition to Pot Legalization in Colorado. The Nation, Sep 18, 2012.
    https://www.thenation.com/article/archive/gop-mogul-behind-drug-rehab-torture-centers-bankrolling-opposition-pot-legalization-colo/
  139. 139
    Journalism (public records)
    Mower L, Glorioso A. Donors gave big to DeSantis' marijuana campaign after getting $10M from Hope Florida. Miami Herald / Herald-Times Tallahassee Bureau, Apr 11, 2025.
    https://www.miamiherald.com/news/politics-government/article304020886.html
  140. 140
    Journalism (federal lobbying disclosures)
    Angell T. Alcohol Industry Steps Up Lobbying On Hemp Drinks As Congress Debates THC Ban. Marijuana Moment, Oct 21, 2025.
    https://www.marijuanamoment.net/alcohol-industry-steps-up-lobbying-on-hemp-drinks-as-congress-debates-thc-ban/
  141. 141
    Journalism
    Jaeger K. Alcohol Industry Groups Push Congress To Ban Intoxicating Hemp Products—At Least Until Federal Regulations Are Enacted. Marijuana Moment, Nov 4, 2025.
    https://www.marijuanamoment.net/alcohol-industry-groups-push-congress-to-ban-intoxicating-hemp-products-at-least-until-federal-regulations-are-enacted/
  142. 142
    Video (primary source)
    American Bridge 21st Century (@American_Bridge). Post and 52-second video of then-Rep. Marsha Blackburn (R-TN) in a hotel lobby, June 8, 2018.
    https://x.com/American_Bridge/status/1005155869372403712
  143. 143
    Opinion (cites Center for Responsive Politics)
    Pfeffer AN. Marsha Blackburn cares more about drug sellers than Tennesseans torn by opioid crisis. Knox News / Knoxville News Sentinel, March 12, 2018. Cites Center for Responsive Politics: $711,385 in campaign contributions from the pharmaceutical industry since 2002; also $15,000 from McKesson and $17,500 from Cardinal Health.
    https://www.knoxnews.com/story/opinion/columnists/2018/03/12/opinion-marsha-blackburn-cares-more-drug-sellers-than-tennesseans-torn-opioid-crisis/400950002/
  144. 144
    News (Associated Press)
    Schroeder O. Blackburn says it would be 'absurd' to return pharma money. Associated Press, Oct. 27, 2017. Reports a Tennessean review finding at least $96,000 since 2012 from PACs affiliated with or representing the largest opioid manufacturers and distributors, and quotes Blackburn calling questions about returning the money “absolutely absurd.”
    https://apnews.com/general-news-ebf0e71b0c2747538e4e7be7021c4319
  145. 145
    Investigative journalism
    Higham S, Bernstein L. The drug industry’s triumph over the DEA. The Washington Post and CBS 60 Minutes, Oct. 15, 2017.
    https://www.washingtonpost.com/graphics/2017/investigations/dea-drug-industry-congress/
  146. 146
    News (cites campaign-finance records)
    Sohn P. Marsha Blackburn's opioid sleight of hand. Chattanooga Times Free Press, Oct. 17, 2017. Reports Blackburn received $120,000 in campaign contributions from the pharmaceutical industry between 2013 and June 2017, in the context of the Washington Post / 60 Minutes investigation.
    https://www.timesfreepress.com/news/2017/oct/17/sohn-marshblackburns-opioid-sleight-hand/
  147. 147
    Fact-check
    Greenberg J. Phil Bredesen says Marsha Blackburn weakened DEA opioid enforcement. PolitiFact, Sept. 18, 2018. Reports drug-distributor donations to Blackburn of $6,000 in 2012, rising to $22,000 a few years later, and just shy of $1.3 million in lobbying in 2014–2016 by two distribution companies and the Healthcare Distribution Alliance on the bill she championed.
    https://www.politifact.com/factchecks/2018/sep/18/phil-bredesen/bredesen-blackburn-weakened-dea-opioid-enforcement/
  148. 148
    Campaign-finance database
    OpenSecrets. Pharmaceuticals/Health Products recipients, Senate, all cycles. Lists Marsha Blackburn (R-TN) at $1,361,176 from PACs and individuals giving $200 or more. Page states figures are for the 1990–2024 election cycles based on FEC data released March 20, 2023.
    https://www.opensecrets.org/industries/summary?cycle=All&ind=H04&mem=Y&recipdetail=S